RecruitingNot Applicable

PTGS1 Genetic Variation and Increased Risk for Persistent Pulmonary Hypertension of the Newborn

United States200 participantsStarted 2006-01

Plain-language summary

The purpose of this study is to determine if normally occurring variations in a specific gene called PTGS-1 are associated with an increased risk of narrowing of the ductus arteriosus from exposure to over-the-counter pain medicines (NSAIDs).

Who can participate

Age range12 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Infants born greater than or equal to 34 weeks gestational age diagnosed with PPHN and normal, healthy infants born greater than or equal to 34 weeks gestational age. Exclusion Criteria: * Patients will be excluded if they are diagnosed with lethal congenital anomalies * structural congenital heart disease except presence of patent ductus arteriosus (PDA) or patent foramen ovale * structural gastrointestinal tract abnormality that could interfere with meconium passage * congenital anomalies such as diaphragmatic hernia, Potter's syndrome, or pulmonary hypoplasia

What they're measuring

To determine whether or not a variation in the prostaglandin G/H Synthase-1 gene contributes to the incidence of PPHN in infants who are exposed to NSAIDs in utero.

Timeframe: participants will be followed for the duration of hospital stay, an expected average of 3 weeks

Trial details

NCT IDNCT00710177

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-12

Contact for this trial

G. Ganesh Konduri, MD

414-266-6820 gkonduri@mcw.edu

View on ClinicalTrials.gov More Persistent Pulmonary Hypertension of the Newborn trials